The following is a summary of “Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients ...
The global fusion biopsy market, valued at US$0.61 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching ...
Mark Hinton, CTO at Lucida Medical, said: “Pi is medical device software that is CE-approved for use in clinics. We developed ...
Adenocarcinoma grows in the tissue of the prostate gland, but other types of cancer can also start in the prostate or spread ...
Bill Faulkner had long approached prostate cancer testing with skepticism. For almost a decade, the 73-year-old had avoided ...
Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on prostate cancer active surveillance.
The 18-gene MyProstateScore 2.0 biomarker test was designed to reduce overdiagnosis of low-grade prostate cancers.
The PAIR-1 study shows that the Pi AI software, now in use in NHS and European hospitals, is the first commercial product of ...
Scientists at Aberdeen University create pioneering new scanner 50 years after the university invented the first MRI scanner ...
Advancements in technology like MRI and digital mammography enable improved accuracy ... due to the rising incidence of prostate cancer in men. The demand for prostate biopsy is taking place for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback